Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir
Chien‐Hung Chen(Chang Gung University), Cheng‐Yuan Peng(China Medical University), Tsung‐Hui Hu(National Sun Yat-sen University), Jing‐Houng Wang(Chang Gung University), Mei–Hsuan Lee(National Taiwan University), Chia‐Hsin Lin(Chang Gung University), Wen-Pang Su(China Medical University), Hsueh‐Chou Lai(China Medical University), Chao‐Hung Hung(Chang Gung University), Chuan-Mo Lee(Kaohsiung Chang Gung Memorial Hospital), Sheng‐Nan Lu(Chang Gung University)
Cited by 61
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653